Literature DB >> 31239286

Life is complicated: so is apoCIII.

Gissette Reyes-Soffer1, Henry N Ginsberg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31239286      PMCID： PMC6672043          DOI： 10.1194/jlr.C119000214

Source DB:  PubMed          Journal:  J Lipid Res        ISSN： 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  21 in total

1.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

2.  Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.

Authors:  Mark J Graham; Richard G Lee; Thomas A Bell; Wuxia Fu; Adam E Mullick; Veronica J Alexander; Walter Singleton; Nick Viney; Richard Geary; John Su; Brenda F Baker; Jennifer Burkey; Stanley T Crooke; Rosanne M Crooke
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

3.  Endogenous ApoE expression modulates adipocyte triglyceride content and turnover.

Authors:  Zhi Hua Huang; Catherine A Reardon; Theodore Mazzone
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

4.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

5.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

6.  Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Authors:  Daniel Gaudet; Veronica J Alexander; Brenda F Baker; Diane Brisson; Karine Tremblay; Walter Singleton; Richard S Geary; Steven G Hughes; Nicholas J Viney; Mark J Graham; Rosanne M Crooke; Joseph L Witztum; John D Brunzell; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-07-30       Impact factor: 91.245

7.  Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.

Authors:  Karin Conde-Knape; Kenta Okada; Rajasekhar Ramakrishnan; Neil S Shachter
Journal:  J Lipid Res       Date:  2004-09-01       Impact factor: 5.922

8.  Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

Authors:  K Aalto-Setälä; E A Fisher; X Chen; T Chajek-Shaul; T Hayek; R Zechner; A Walsh; R Ramakrishnan; H N Ginsberg; J L Breslow
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

9.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

Authors:  Jacy Crosby; Gina M Peloso; Paul L Auer; David R Crosslin; Nathan O Stitziel; Leslie A Lange; Yingchang Lu; Zheng-zheng Tang; He Zhang; George Hindy; Nicholas Masca; Kathleen Stirrups; Stavroula Kanoni; Ron Do; Goo Jun; Youna Hu; Hyun Min Kang; Chenyi Xue; Anuj Goel; Martin Farrall; Stefano Duga; Pier Angelica Merlini; Rosanna Asselta; Domenico Girelli; Oliviero Olivieri; Nicola Martinelli; Wu Yin; Dermot Reilly; Elizabeth Speliotes; Caroline S Fox; Kristian Hveem; Oddgeir L Holmen; Majid Nikpay; Deborah N Farlow; Themistocles L Assimes; Nora Franceschini; Jennifer Robinson; Kari E North; Lisa W Martin; Mark DePristo; Namrata Gupta; Stefan A Escher; Jan-Håkan Jansson; Natalie Van Zuydam; Colin N A Palmer; Nicholas Wareham; Werner Koch; Thomas Meitinger; Annette Peters; Wolfgang Lieb; Raimund Erbel; Inke R Konig; Jochen Kruppa; Franziska Degenhardt; Omri Gottesman; Erwin P Bottinger; Christopher J O'Donnell; Bruce M Psaty; Christie M Ballantyne; Goncalo Abecasis; Jose M Ordovas; Olle Melander; Hugh Watkins; Marju Orho-Melander; Diego Ardissino; Ruth J F Loos; Ruth McPherson; Cristen J Willer; Jeanette Erdmann; Alistair S Hall; Nilesh J Samani; Panos Deloukas; Heribert Schunkert; James G Wilson; Charles Kooperberg; Stephen S Rich; Russell P Tracy; Dan-Yu Lin; David Altshuler; Stacey Gabriel; Deborah A Nickerson; Gail P Jarvik; L Adrienne Cupples; Alex P Reiner; Eric Boerwinkle; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2014-06-18       Impact factor: 91.245

10.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

Authors:  Anders Berg Jørgensen; Ruth Frikke-Schmidt; Børge G Nordestgaard; Anne Tybjærg-Hansen
Journal:  N Engl J Med       Date:  2014-06-18       Impact factor: 91.245
View more
  3 in total

Review 1.  Review of How Genetic Research on Segmental Progeroid Syndromes Has Documented Genomic Instability as a Hallmark of Aging But Let Us Now Pursue Antigeroid Syndromes!

Authors:  George M Martin; Fuki M Hisama; Junko Oshima
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-01-18       Impact factor: 6.053

Review 2.  Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.

Authors:  Bai-Hui Zhang; Fan Yin; Ya-Nan Qiao; Shou-Dong Guo
Journal:  Front Mol Biosci       Date:  2022-05-25

Review 3.  Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy.

Authors:  Leinys S Santos-Baez; Henry N Ginsberg
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-02       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.